Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia

ABSTRACT: Key Points• Multiple mechanisms of acquired CD19 mutations and splicing contribute to CD19 loss and relapse to blinatumomab.• Identification of CD19 ex2part levels represents a new biomarker predictive of resistance or likely failure of blinatumomab

PROVIDER: EGAS00001004027 | EGA |

REPOSITORIES: EGA